



Biocon Limited

20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T: 91 80 2808 2808
F: 91 80 2852 3423

CIN: L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2026-27/12

May 04, 2026

To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code – 532523	To, The Secretary National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex, Mumbai – 400 051 Scrip Symbol – Biocon
--	--

Dear Sir/Madam,

Subject: Intimation pursuant to Regulation 29(1) of SEBI Listing Regulations

This is further to our letter dated April 23, 2026, intimating the date of Board meeting to be held on May 07, 2026. Pursuant to Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform you that the Board of Directors of the Company at the aforesaid meeting shall also consider investment in Biocon Biologics Limited (‘BBL’), an unlisted material subsidiary of the Company, by way of purchase or acquisition of equity shares of BBL, for consideration other than cash through issuance and allotment of fully paid-up equity shares of the Company on a preferential allotment basis through private placement including determination of issue price, in accordance with Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Approval of shareholders of the Company, as may be required in this regard, shall be obtained through Postal Ballot, the notice of which shall be submitted in due course.

The above-mentioned information will also be available on website of the Company at www.biocon.com.

Request you to take the above intimation on record.

Thanking you.

For **Biocon Limited**

Rajesh U. Shanoy
Company Secretary and Compliance Officer
M. No.: ACS 16328